



ATTORNEYS AT LAW
230 PARK AVENUE, 10TH FLOOR
NEW YORK, NEW YORK 10169
T: 646-627-7326 F: 646.224.9844
WWW.OFSINKLLC.COM

April 10, 2017

By OTC Disclosure and News Services

OTC Markets Group Inc.
304 Hudson Street, 3rd Floor
New York, NY 10013

Re: Permanent Technologies, Inc. (“PERT”)

Ladies and Gentlemen:

We are counsel to Permanent Technologies, Inc., a Nevada corporation (the “Company” or the “Issuer”). We are a legal resident of the United States and licensed to practice law in New York. We note that we are members of the Bar of the State of New York and do not represent ourselves to be experts in the laws of any other jurisdiction, except for the laws of the United States of America.

We provide general legal counsel to the Company pertaining to its business affairs, including, but not limited to, the purpose of rendering this opinion letter (this “Letter”). OTC Markets Group Inc. (“OTC Markets Group”) may rely upon this Letter in determining whether the Company has made adequate current information publicly available in accordance with Rule 144(c)(2) under the Securities Act of 1933 (the “Securities Act”).

In rendering this Letter, we have (a) assumed (i) the genuineness of all signatures on all documents examined by us, (ii) the authenticity of all documents submitted to us as originals, and (iii) the conformity to original documents of all documents submitted to us as photostatic or conformed copies and the authenticity of the originals of such copies; and (b) relied on (i) certificates of public officials and (ii) as to matters of fact, statements and certificates of officers and representatives of the Company, including, but not limited to, the issuer’s certifications by its president regarding filing with OTC Disclosure and News Service, dated March 31, 2017.

The opinions and conclusions contained in this Letter are based upon documentation and facts made available by the Company to us, and are solely based on the accuracy of those documents and facts. In the event that the facts and information in any or all of such documents are determined not to be true, this opinion is rescinded and to be deemed null and void.

We have further addressed such questions of law that we have deemed necessary and/or appropriate for the purpose of rendering this Letter.

This Letter is respectfully submitted on behalf of the Company to be posted by the Issuer and published, accompanying the Issuer's disclosure(s), through the OTC Disclosure and News Service in accordance with and/or pursuant to OTC Disclosure and News Service guidelines.

This Letter covers the laws of the United States and does not depend on another law firm's opinion or letter. We are permitted to practice before the U.S. Securities and Exchange Commission (the "SEC") without prohibition.

Joseph Mastanduno, Controller of the Company, is a Certified Public Accountant, licensed by the State of New York. He is responsible for the preparation of the financial statements of the Company along with the appropriate notes. The financial statements are not audited, but have been prepared in accordance with generally accepted accounting principles.

The Company's transfer agent is Securities Transfer Corporation ("STC"). STC is duly registered with the SEC. We have relied upon and reviewed a shareholder list supplied by STC which we used to confirm the number of the outstanding shares as set forth in the Information (as defined below).

We have (i) met personally with the management of the Company and the majority of the directors; (ii) reviewed the information described further below, as filed by the Issuer, with the OTC Disclosure and News Service; and (iii) discussed the Information with management and the majority of the directors of the Company.

To the best of our knowledge and after inquiry of management and the directors of the Company, no 5% holder of securities of the Company, or the Company is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

Our managing member, Darren Ofsink, was indicted on November 4, 2015 based on allegations of Conspiracy to Commit Securities Fraud, Conspiracy to Commit Mail and Wire Fraud and Securities Fraud and the Securities and Exchange Commission has amended an existing complaint to add Mr. Ofsink as a defendant based on allegations of a violation of Section 5 of the Securities Act of 1933, as amended.

The documents containing information concerning the Company that are publicly available and which we have reviewed as filed with the OTC Disclosure and News Service in preparation for rendering this Letter (the "Information") are set forth herein below along with the date each document was posted through the OTC Disclosure and News Service.

Type of Document filed	Document Description	Date Released/
------------------------	----------------------	----------------

		Posted
Annual Report	Disclosure Statement December 31, 2016	March 31, 2017
Annual Report	Financial Statement December 31, 2016	March 31, 2017

Based upon the foregoing and subject to the qualifications hereinafter set forth, we are of the opinion that the Information reviewed, as herein described and detailed above as filed by the Company with and published by the OTC Disclosure and News Service, except that no opinion is given with respect to Rule 15c2-11(a)(5)(xiv), (xv) and (xvi) under the Securities Exchange Act of 1934 (the “Exchange Act”):

1. Constitutes “adequate current public information” concerning the Issuer’s securities and the Issuer and “is available” within the meaning of Rule 144(c)(2) under the Securities Act,
2. Includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Issuer’s securities under Rule 15c2-11 under the Exchange Act,
3. Complies as to form with the OTC Markets Group’s Guidelines for Providing Adequate Current Information, and
4. Has been posted through the OTC Disclosure and News Service.

This Letter may be relied upon by OTC Markets Group, but may not be used or relied on by any other person for any other purpose whatsoever, without in each instance the undersigned’s prior written consent. OTC Markets Group is granted full and complete permission and rights to publish this Letter through the OTC Disclosure and News Service for viewing by the public or regulators.

Very truly yours,

/s/ OFSINK, LLC

OFSINK, LLC